Ihab Kamel
Concepts (659)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 125 | 2025 | 776 | 21.680 |
Why?
| | Carcinoma, Hepatocellular | 75 | 2025 | 370 | 16.550 |
Why?
| | Chemoembolization, Therapeutic | 43 | 2024 | 88 | 12.060 |
Why?
| | Diffusion Magnetic Resonance Imaging | 48 | 2025 | 158 | 10.990 |
Why?
| | Magnetic Resonance Imaging | 141 | 2025 | 3926 | 10.350 |
Why?
| | Pancreatic Neoplasms | 34 | 2024 | 944 | 5.790 |
Why?
| | Cholangiocarcinoma | 19 | 2024 | 110 | 5.250 |
Why?
| | Contrast Media | 61 | 2025 | 493 | 4.800 |
Why?
| | Image Enhancement | 29 | 2018 | 198 | 4.540 |
Why?
| | Tomography, X-Ray Computed | 70 | 2025 | 2786 | 4.390 |
Why?
| | Image Interpretation, Computer-Assisted | 24 | 2026 | 295 | 4.020 |
Why?
| | Carcinoma, Pancreatic Ductal | 14 | 2024 | 297 | 4.020 |
Why?
| | Bile Duct Neoplasms | 15 | 2023 | 132 | 3.820 |
Why?
| | Liver | 41 | 2026 | 1864 | 3.770 |
Why?
| | Neuroendocrine Tumors | 12 | 2021 | 122 | 3.130 |
Why?
| | Liver Cirrhosis | 20 | 2024 | 278 | 3.020 |
Why?
| | Elasticity Imaging Techniques | 9 | 2023 | 59 | 2.780 |
Why?
| | Liver Diseases | 17 | 2023 | 304 | 2.750 |
Why?
| | Pancreatic Cyst | 12 | 2023 | 50 | 2.570 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 16 | 2022 | 60 | 2.430 |
Why?
| | Tumor Burden | 14 | 2024 | 326 | 2.360 |
Why?
| | Retrospective Studies | 105 | 2026 | 17438 | 2.350 |
Why?
| | Cholangitis, Sclerosing | 5 | 2020 | 56 | 2.320 |
Why?
| | Middle Aged | 180 | 2026 | 36619 | 2.320 |
Why?
| | Gadolinium DTPA | 20 | 2025 | 70 | 2.290 |
Why?
| | Humans | 338 | 2026 | 146342 | 2.160 |
Why?
| | Algorithms | 21 | 2026 | 1849 | 2.100 |
Why?
| | Aged | 142 | 2025 | 26432 | 2.060 |
Why?
| | Cystadenoma, Serous | 3 | 2024 | 18 | 1.930 |
Why?
| | Pancreatitis | 8 | 2023 | 146 | 1.910 |
Why?
| | Sensitivity and Specificity | 37 | 2025 | 1998 | 1.910 |
Why?
| | Male | 196 | 2026 | 73396 | 1.790 |
Why?
| | Female | 207 | 2026 | 79499 | 1.770 |
Why?
| | Reproducibility of Results | 41 | 2025 | 3416 | 1.740 |
Why?
| | Positron-Emission Tomography | 10 | 2023 | 343 | 1.710 |
Why?
| | Pancreas | 13 | 2024 | 343 | 1.680 |
Why?
| | Esophageal Neoplasms | 13 | 2025 | 351 | 1.650 |
Why?
| | Treatment Outcome | 60 | 2025 | 11821 | 1.530 |
Why?
| | Colorectal Neoplasms | 10 | 2021 | 874 | 1.520 |
Why?
| | Spleen | 4 | 2020 | 503 | 1.520 |
Why?
| | Adult | 122 | 2026 | 41087 | 1.480 |
Why?
| | Carcinoma, Renal Cell | 6 | 2024 | 231 | 1.470 |
Why?
| | Diagnosis, Differential | 27 | 2025 | 1503 | 1.460 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 7 | 2020 | 24 | 1.450 |
Why?
| | Incidental Findings | 5 | 2024 | 81 | 1.450 |
Why?
| | Kidney Neoplasms | 7 | 2025 | 419 | 1.440 |
Why?
| | Splenic Diseases | 3 | 2019 | 9 | 1.430 |
Why?
| | Iron Overload | 4 | 2024 | 19 | 1.370 |
Why?
| | Aged, 80 and over | 55 | 2024 | 8391 | 1.330 |
Why?
| | Adenoma, Liver Cell | 4 | 2024 | 4 | 1.330 |
Why?
| | Embolization, Therapeutic | 11 | 2022 | 246 | 1.320 |
Why?
| | Hepatectomy | 19 | 2021 | 256 | 1.270 |
Why?
| | Liver Transplantation | 18 | 2025 | 751 | 1.250 |
Why?
| | Diagnostic Imaging | 15 | 2024 | 340 | 1.240 |
Why?
| | Image Processing, Computer-Assisted | 17 | 2025 | 778 | 1.200 |
Why?
| | Lymphatic Metastasis | 5 | 2024 | 335 | 1.200 |
Why?
| | Ultrasonography | 8 | 2026 | 788 | 1.200 |
Why?
| | Angiomyolipoma | 3 | 2018 | 21 | 1.170 |
Why?
| | Imaging, Three-Dimensional | 16 | 2025 | 582 | 1.160 |
Why?
| | Ureteral Obstruction | 2 | 2020 | 62 | 1.150 |
Why?
| | Biomarkers, Tumor | 9 | 2025 | 1339 | 1.140 |
Why?
| | Predictive Value of Tests | 25 | 2025 | 2113 | 1.120 |
Why?
| | Focal Nodular Hyperplasia | 5 | 2018 | 7 | 1.110 |
Why?
| | Uterine Neoplasms | 4 | 2023 | 98 | 1.090 |
Why?
| | Magnetic Resonance Angiography | 4 | 2025 | 249 | 1.090 |
Why?
| | Adipose Tissue | 7 | 2024 | 642 | 1.080 |
Why?
| | Rectal Neoplasms | 6 | 2024 | 160 | 1.080 |
Why?
| | Adenoma | 4 | 2024 | 210 | 1.080 |
Why?
| | Organometallic Compounds | 4 | 2018 | 110 | 1.070 |
Why?
| | ROC Curve | 19 | 2026 | 617 | 1.060 |
Why?
| | Prognosis | 26 | 2024 | 4351 | 1.050 |
Why?
| | Neoadjuvant Therapy | 10 | 2025 | 475 | 1.040 |
Why?
| | Neoplasm Staging | 20 | 2024 | 1488 | 1.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1998 | 1.030 |
Why?
| | Kidney Diseases | 3 | 2020 | 428 | 1.020 |
Why?
| | Bile Ducts, Intrahepatic | 13 | 2023 | 62 | 1.010 |
Why?
| | Living Donors | 6 | 2021 | 216 | 0.970 |
Why?
| | Kidney | 10 | 2026 | 1498 | 0.970 |
Why?
| | Yttrium Radioisotopes | 5 | 2022 | 64 | 0.950 |
Why?
| | Fibrosis | 10 | 2026 | 568 | 0.950 |
Why?
| | Survival Rate | 19 | 2024 | 2092 | 0.950 |
Why?
| | Cardiomyopathy, Hypertrophic | 9 | 2018 | 144 | 0.940 |
Why?
| | Carcinoma | 6 | 2023 | 225 | 0.910 |
Why?
| | Leiomyoma | 3 | 2023 | 62 | 0.890 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 259 | 0.880 |
Why?
| | Renal Artery | 3 | 2025 | 42 | 0.880 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.880 |
Why?
| | Coronavirus Infections | 2 | 2020 | 379 | 0.880 |
Why?
| | Nomograms | 2 | 2024 | 59 | 0.860 |
Why?
| | Societies, Medical | 17 | 2025 | 907 | 0.860 |
Why?
| | Neoplasm Grading | 6 | 2024 | 313 | 0.850 |
Why?
| | Magnetic Resonance Spectroscopy | 8 | 2022 | 627 | 0.840 |
Why?
| | Infusions, Intra-Arterial | 6 | 2019 | 61 | 0.800 |
Why?
| | Adenomyosis | 1 | 2023 | 7 | 0.800 |
Why?
| | Uterine Artery Embolization | 1 | 2023 | 9 | 0.800 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2019 | 74 | 0.800 |
Why?
| | Prospective Studies | 33 | 2025 | 8123 | 0.790 |
Why?
| | Gallbladder Neoplasms | 1 | 2023 | 20 | 0.790 |
Why?
| | Liver Regeneration | 6 | 2017 | 41 | 0.790 |
Why?
| | Leiomyosarcoma | 2 | 2022 | 30 | 0.780 |
Why?
| | Doxorubicin | 9 | 2014 | 416 | 0.780 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 2219 | 0.760 |
Why?
| | Adenocarcinoma | 7 | 2020 | 927 | 0.740 |
Why?
| | Neoplasms | 7 | 2021 | 2954 | 0.730 |
Why?
| | Hemangioma | 4 | 2022 | 46 | 0.690 |
Why?
| | Positron Emission Tomography Computed Tomography | 5 | 2025 | 122 | 0.690 |
Why?
| | Evidence-Based Medicine | 13 | 2025 | 731 | 0.690 |
Why?
| | Immunotherapy | 2 | 2024 | 671 | 0.680 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2019 | 218 | 0.670 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2022 | 164 | 0.660 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2023 | 352 | 0.660 |
Why?
| | Risk Assessment | 13 | 2024 | 3712 | 0.660 |
Why?
| | Patient Safety | 1 | 2024 | 352 | 0.660 |
Why?
| | Meglumine | 3 | 2018 | 18 | 0.650 |
Why?
| | Catheter Ablation | 9 | 2018 | 355 | 0.650 |
Why?
| | Multidetector Computed Tomography | 6 | 2024 | 40 | 0.640 |
Why?
| | Lupus Nephritis | 3 | 2026 | 67 | 0.630 |
Why?
| | Obesity, Abdominal | 1 | 2020 | 48 | 0.620 |
Why?
| | Adenocarcinoma, Mucinous | 3 | 2018 | 76 | 0.620 |
Why?
| | Diffusion Tensor Imaging | 2 | 2021 | 83 | 0.620 |
Why?
| | Subcutaneous Fat | 1 | 2020 | 80 | 0.620 |
Why?
| | Vascular Diseases | 2 | 2017 | 252 | 0.610 |
Why?
| | Necrosis | 5 | 2021 | 243 | 0.610 |
Why?
| | Hepatic Artery | 5 | 2013 | 53 | 0.590 |
Why?
| | Observer Variation | 9 | 2020 | 356 | 0.580 |
Why?
| | Young Adult | 33 | 2026 | 14330 | 0.580 |
Why?
| | Follow-Up Studies | 21 | 2022 | 5439 | 0.580 |
Why?
| | Radiology | 6 | 2019 | 175 | 0.570 |
Why?
| | Abdominal Pain | 5 | 2025 | 149 | 0.570 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 41 | 0.560 |
Why?
| | Adenoma, Oxyphilic | 1 | 2018 | 7 | 0.550 |
Why?
| | Biomarkers | 10 | 2026 | 4340 | 0.540 |
Why?
| | Biliary Tract Diseases | 4 | 2019 | 32 | 0.540 |
Why?
| | Angiography | 5 | 2013 | 206 | 0.540 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 57 | 0.530 |
Why?
| | Phenylurea Compounds | 3 | 2015 | 122 | 0.520 |
Why?
| | Niacinamide | 3 | 2015 | 103 | 0.520 |
Why?
| | Pancreatic Ducts | 2 | 2015 | 81 | 0.510 |
Why?
| | Fatty Liver | 6 | 2017 | 252 | 0.510 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.510 |
Why?
| | Whole Body Imaging | 3 | 2018 | 29 | 0.510 |
Why?
| | Tachycardia, Ventricular | 5 | 2022 | 179 | 0.510 |
Why?
| | Actins | 1 | 2019 | 422 | 0.500 |
Why?
| | Biopsy | 7 | 2026 | 1075 | 0.500 |
Why?
| | Magnetic Resonance Imaging, Cine | 5 | 2022 | 214 | 0.490 |
Why?
| | Defibrillators, Implantable | 6 | 2022 | 393 | 0.490 |
Why?
| | Lymph Nodes | 5 | 2024 | 511 | 0.490 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 3 | 2025 | 21 | 0.480 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 11 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2023 | 1160 | 0.480 |
Why?
| | Early Detection of Cancer | 9 | 2024 | 506 | 0.470 |
Why?
| | Watchful Waiting | 1 | 2016 | 90 | 0.460 |
Why?
| | Liver Function Tests | 4 | 2025 | 103 | 0.460 |
Why?
| | Heart Ventricles | 8 | 2018 | 762 | 0.460 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2016 | 99 | 0.450 |
Why?
| | Kaplan-Meier Estimate | 11 | 2018 | 970 | 0.450 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2025 | 121 | 0.430 |
Why?
| | Leucovorin | 2 | 2024 | 98 | 0.420 |
Why?
| | Sarcopenia | 6 | 2016 | 100 | 0.420 |
Why?
| | Choledochal Cyst | 3 | 2022 | 16 | 0.420 |
Why?
| | Bile Ducts | 3 | 2019 | 66 | 0.420 |
Why?
| | Abdomen | 2 | 2013 | 142 | 0.410 |
Why?
| | Multimodal Imaging | 3 | 2023 | 137 | 0.410 |
Why?
| | Esophageal and Gastric Varices | 2 | 2024 | 34 | 0.410 |
Why?
| | United States | 33 | 2026 | 16136 | 0.400 |
Why?
| | Neoplasm Invasiveness | 4 | 2020 | 504 | 0.400 |
Why?
| | Fluorouracil | 2 | 2024 | 231 | 0.390 |
Why?
| | Biliary Tract Neoplasms | 1 | 2013 | 30 | 0.390 |
Why?
| | Aspartate Aminotransferases | 1 | 2013 | 86 | 0.390 |
Why?
| | Risk Factors | 27 | 2026 | 10921 | 0.390 |
Why?
| | Survival Analysis | 6 | 2019 | 1378 | 0.390 |
Why?
| | Proportional Hazards Models | 11 | 2018 | 1331 | 0.380 |
Why?
| | Alanine Transaminase | 1 | 2013 | 151 | 0.380 |
Why?
| | Choline | 2 | 2011 | 136 | 0.380 |
Why?
| | Organ Size | 6 | 2019 | 465 | 0.370 |
Why?
| | Phantoms, Imaging | 5 | 2021 | 160 | 0.370 |
Why?
| | Ventricular Fibrillation | 3 | 2018 | 63 | 0.360 |
Why?
| | Iron | 3 | 2024 | 359 | 0.360 |
Why?
| | Ventricular Function, Right | 3 | 2020 | 300 | 0.360 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1591 | 0.350 |
Why?
| | Death, Sudden, Cardiac | 5 | 2022 | 242 | 0.350 |
Why?
| | Models, Biological | 2 | 2016 | 1761 | 0.350 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2025 | 241 | 0.350 |
Why?
| | Authorship | 1 | 2012 | 51 | 0.340 |
Why?
| | Carcinoma in Situ | 3 | 2021 | 45 | 0.340 |
Why?
| | Area Under Curve | 3 | 2019 | 335 | 0.340 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2011 | 26 | 0.340 |
Why?
| | Myocardial Perfusion Imaging | 3 | 2025 | 50 | 0.340 |
Why?
| | Ethiodized Oil | 3 | 2021 | 10 | 0.340 |
Why?
| | Endosonography | 5 | 2020 | 160 | 0.330 |
Why?
| | Cystadenoma | 3 | 2023 | 5 | 0.330 |
Why?
| | Arrhythmias, Cardiac | 5 | 2022 | 358 | 0.320 |
Why?
| | Publishing | 1 | 2012 | 117 | 0.320 |
Why?
| | Cohort Studies | 11 | 2024 | 6077 | 0.320 |
Why?
| | Embolism | 1 | 2011 | 49 | 0.320 |
Why?
| | Echo-Planar Imaging | 3 | 2023 | 24 | 0.320 |
Why?
| | Radiopharmaceuticals | 4 | 2019 | 210 | 0.320 |
Why?
| | Tomography, Spiral Computed | 4 | 2007 | 30 | 0.320 |
Why?
| | Angiomatosis | 1 | 2010 | 5 | 0.310 |
Why?
| | Non-alcoholic Fatty Liver Disease | 4 | 2021 | 265 | 0.310 |
Why?
| | SEER Program | 3 | 2024 | 233 | 0.310 |
Why?
| | Bevacizumab | 3 | 2021 | 169 | 0.310 |
Why?
| | Radiologists | 3 | 2024 | 61 | 0.300 |
Why?
| | Breast Neoplasms | 6 | 2021 | 2418 | 0.300 |
Why?
| | Myocardium | 5 | 2018 | 948 | 0.300 |
Why?
| | Periodicals as Topic | 1 | 2012 | 214 | 0.300 |
Why?
| | Disease Progression | 7 | 2019 | 2867 | 0.300 |
Why?
| | Cystadenocarcinoma | 2 | 2023 | 4 | 0.300 |
Why?
| | Software | 4 | 2018 | 676 | 0.290 |
Why?
| | Autoimmune Diseases | 1 | 2013 | 467 | 0.290 |
Why?
| | Kidney Transplantation | 2 | 2025 | 735 | 0.290 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2025 | 248 | 0.280 |
Why?
| | Solitary Fibrous Tumors | 1 | 2008 | 3 | 0.280 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2008 | 30 | 0.280 |
Why?
| | Secretin | 3 | 2019 | 6 | 0.280 |
Why?
| | Eye Neoplasms | 1 | 2008 | 31 | 0.270 |
Why?
| | Radiographic Image Enhancement | 2 | 2012 | 57 | 0.270 |
Why?
| | Artificial Intelligence | 3 | 2022 | 389 | 0.270 |
Why?
| | Chi-Square Distribution | 6 | 2017 | 517 | 0.260 |
Why?
| | Adolescent | 18 | 2026 | 22557 | 0.260 |
Why?
| | Heart Atria | 2 | 2018 | 139 | 0.260 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 48 | 0.260 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 377 | 0.250 |
Why?
| | Rectum | 3 | 2020 | 180 | 0.250 |
Why?
| | Leiomyomatosis | 1 | 2007 | 4 | 0.250 |
Why?
| | Hepatic Veins | 3 | 2003 | 28 | 0.250 |
Why?
| | Neovascularization, Pathologic | 2 | 2008 | 287 | 0.250 |
Why?
| | Myocardial Contraction | 2 | 2018 | 292 | 0.240 |
Why?
| | Psoas Muscles | 3 | 2015 | 24 | 0.240 |
Why?
| | Pancreatectomy | 5 | 2020 | 289 | 0.240 |
Why?
| | RNA, Small Cytoplasmic | 1 | 2026 | 7 | 0.240 |
Why?
| | Antibodies, Antinuclear | 1 | 2026 | 60 | 0.240 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2016 | 38 | 0.230 |
Why?
| | Kidney Tubules | 1 | 2026 | 117 | 0.220 |
Why?
| | Models, Statistical | 3 | 2019 | 669 | 0.220 |
Why?
| | Liver Failure | 2 | 2016 | 79 | 0.220 |
Why?
| | Ribonucleoproteins | 1 | 2026 | 106 | 0.220 |
Why?
| | Amyloidosis | 1 | 2025 | 43 | 0.210 |
Why?
| | Proteinuria | 1 | 2025 | 103 | 0.210 |
Why?
| | Portal Vein | 6 | 2012 | 123 | 0.210 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4580 | 0.210 |
Why?
| | Collateral Circulation | 1 | 2004 | 20 | 0.210 |
Why?
| | Cardiomyopathies | 2 | 2025 | 340 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2025 | 124 | 0.200 |
Why?
| | Computed Tomography Angiography | 1 | 2025 | 151 | 0.200 |
Why?
| | Pancreas, Exocrine | 1 | 2024 | 7 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2537 | 0.200 |
Why?
| | Protons | 4 | 2020 | 96 | 0.200 |
Why?
| | Hypertension, Portal | 1 | 2004 | 66 | 0.200 |
Why?
| | Safety Management | 1 | 2024 | 130 | 0.200 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 83 | 0.200 |
Why?
| | Atrophy | 3 | 2026 | 199 | 0.190 |
Why?
| | Feasibility Studies | 7 | 2024 | 1135 | 0.190 |
Why?
| | Cholecystitis, Acute | 1 | 2023 | 26 | 0.190 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 143 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2025 | 246 | 0.190 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 134 | 0.190 |
Why?
| | Severity of Illness Index | 5 | 2026 | 2921 | 0.190 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2023 | 62 | 0.180 |
Why?
| | alpha-Fetoproteins | 2 | 2013 | 42 | 0.180 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 64 | 0.180 |
Why?
| | Electrocardiography | 4 | 2020 | 667 | 0.180 |
Why?
| | Hemangioma, Cavernous | 1 | 2022 | 11 | 0.180 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2022 | 8 | 0.180 |
Why?
| | Cysts | 1 | 2023 | 108 | 0.180 |
Why?
| | Time Factors | 11 | 2018 | 7109 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2026 | 279 | 0.180 |
Why?
| | Statistics, Nonparametric | 5 | 2019 | 426 | 0.180 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 560 | 0.180 |
Why?
| | Graft Rejection | 1 | 2025 | 516 | 0.180 |
Why?
| | Hemodynamics | 2 | 2025 | 1114 | 0.170 |
Why?
| | Ultrasonography, Mammary | 1 | 2021 | 17 | 0.170 |
Why?
| | Pandemics | 2 | 2020 | 1707 | 0.170 |
Why?
| | Melanoma | 1 | 2008 | 765 | 0.170 |
Why?
| | Single-Blind Method | 2 | 2017 | 313 | 0.170 |
Why?
| | Nuclear Medicine | 1 | 2021 | 9 | 0.170 |
Why?
| | Rats | 2 | 2020 | 5586 | 0.160 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2022 | 147 | 0.160 |
Why?
| | Biomedical Research | 2 | 2022 | 729 | 0.160 |
Why?
| | Crohn Disease | 1 | 2024 | 250 | 0.160 |
Why?
| | Semaphorins | 1 | 2021 | 37 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 217 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2022 | 72 | 0.160 |
Why?
| | Reference Values | 2 | 2020 | 796 | 0.160 |
Why?
| | Gadolinium | 4 | 2021 | 78 | 0.160 |
Why?
| | Rabbits | 3 | 2011 | 651 | 0.160 |
Why?
| | Margins of Excision | 1 | 2020 | 55 | 0.160 |
Why?
| | Regression Analysis | 3 | 2018 | 999 | 0.160 |
Why?
| | Italy | 1 | 2020 | 118 | 0.160 |
Why?
| | Maryland | 3 | 2016 | 67 | 0.160 |
Why?
| | Kidney Cortex | 1 | 2020 | 27 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 48 | 0.160 |
Why?
| | Kidney Medulla | 1 | 2020 | 28 | 0.160 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.160 |
Why?
| | Ferric Compounds | 2 | 2012 | 55 | 0.150 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.150 |
Why?
| | Inflammation | 1 | 2011 | 2919 | 0.150 |
Why?
| | Ursodeoxycholic Acid | 1 | 2019 | 16 | 0.150 |
Why?
| | Digestive System Neoplasms | 1 | 2019 | 9 | 0.150 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2019 | 37 | 0.150 |
Why?
| | Mammography | 1 | 2021 | 175 | 0.150 |
Why?
| | Combined Modality Therapy | 6 | 2016 | 1271 | 0.150 |
Why?
| | Cardiac-Gated Imaging Techniques | 2 | 2016 | 21 | 0.150 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1036 | 0.150 |
Why?
| | Recurrence | 2 | 2020 | 1133 | 0.150 |
Why?
| | Jaundice | 1 | 2019 | 10 | 0.150 |
Why?
| | Mutation | 4 | 2015 | 4093 | 0.150 |
Why?
| | Prevalence | 5 | 2023 | 2861 | 0.150 |
Why?
| | Radiography | 6 | 2022 | 861 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 604 | 0.140 |
Why?
| | Elasticity | 1 | 2019 | 187 | 0.140 |
Why?
| | Microspheres | 5 | 2016 | 142 | 0.140 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 91 | 0.140 |
Why?
| | Jejunum | 1 | 2019 | 36 | 0.140 |
Why?
| | Vaccines | 1 | 2024 | 389 | 0.140 |
Why?
| | Chronic Disease | 4 | 2017 | 1827 | 0.140 |
Why?
| | Appendicitis | 1 | 2000 | 151 | 0.140 |
Why?
| | Pyridines | 3 | 2021 | 610 | 0.140 |
Why?
| | Mucins | 1 | 2019 | 75 | 0.140 |
Why?
| | Cardiac Imaging Techniques | 2 | 2018 | 24 | 0.140 |
Why?
| | Postoperative Complications | 4 | 2016 | 3034 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 2019 | 63 | 0.140 |
Why?
| | Artifacts | 2 | 2016 | 143 | 0.140 |
Why?
| | Viscera | 1 | 2018 | 17 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 132 | 0.140 |
Why?
| | Pericardium | 1 | 2018 | 59 | 0.130 |
Why?
| | Logistic Models | 4 | 2026 | 2126 | 0.130 |
Why?
| | Equipment Safety | 1 | 2017 | 38 | 0.130 |
Why?
| | Caloric Restriction | 1 | 2019 | 133 | 0.130 |
Why?
| | Hemochromatosis | 1 | 2017 | 9 | 0.130 |
Why?
| | Animals | 10 | 2020 | 38107 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2019 | 339 | 0.130 |
Why?
| | Ventricular Flutter | 1 | 2017 | 2 | 0.130 |
Why?
| | Sepsis | 1 | 2024 | 669 | 0.130 |
Why?
| | Tomography, Emission-Computed | 2 | 2010 | 71 | 0.130 |
Why?
| | Metastasectomy | 1 | 2017 | 19 | 0.130 |
Why?
| | Adrenocortical Adenoma | 1 | 2016 | 2 | 0.120 |
Why?
| | Lymphography | 1 | 2016 | 13 | 0.120 |
Why?
| | Breath Holding | 1 | 2016 | 10 | 0.120 |
Why?
| | Pulmonary Veins | 1 | 2018 | 110 | 0.120 |
Why?
| | Referral and Consultation | 2 | 2013 | 881 | 0.120 |
Why?
| | Lung | 2 | 2020 | 4122 | 0.120 |
Why?
| | Radiotherapy | 2 | 2008 | 209 | 0.120 |
Why?
| | Incidence | 6 | 2020 | 2936 | 0.120 |
Why?
| | Obesity | 3 | 2023 | 3131 | 0.120 |
Why?
| | Electric Countershock | 1 | 2017 | 126 | 0.120 |
Why?
| | Motion | 1 | 2016 | 94 | 0.120 |
Why?
| | Pacemaker, Artificial | 1 | 2017 | 127 | 0.120 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 161 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2017 | 103 | 0.120 |
Why?
| | Disease Management | 3 | 2015 | 651 | 0.120 |
Why?
| | Body Water | 1 | 2016 | 23 | 0.120 |
Why?
| | Pancreatic Juice | 2 | 2012 | 3 | 0.120 |
Why?
| | Benzamides | 1 | 2017 | 226 | 0.120 |
Why?
| | Coronary Circulation | 2 | 2015 | 134 | 0.120 |
Why?
| | Carcinoid Tumor | 2 | 2008 | 21 | 0.120 |
Why?
| | Platelet Count | 1 | 2016 | 95 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 222 | 0.120 |
Why?
| | Multivariate Analysis | 6 | 2017 | 1543 | 0.120 |
Why?
| | Azacitidine | 1 | 2017 | 168 | 0.120 |
Why?
| | Phosphorus | 1 | 2016 | 89 | 0.110 |
Why?
| | Echocardiography | 2 | 2016 | 645 | 0.110 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2016 | 70 | 0.110 |
Why?
| | Adiposity | 1 | 2020 | 533 | 0.110 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2015 | 14 | 0.110 |
Why?
| | Bariatric Surgery | 1 | 2019 | 250 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2015 | 23 | 0.110 |
Why?
| | Fractures, Spontaneous | 2 | 2005 | 15 | 0.110 |
Why?
| | Telomere Homeostasis | 1 | 2015 | 35 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 628 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2018 | 272 | 0.110 |
Why?
| | Body Composition | 1 | 2019 | 689 | 0.110 |
Why?
| | Hospital Costs | 1 | 2016 | 131 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2016 | 124 | 0.110 |
Why?
| | Digestive System Surgical Procedures | 1 | 2016 | 115 | 0.110 |
Why?
| | Insulin | 1 | 2026 | 2525 | 0.110 |
Why?
| | Fractures, Stress | 2 | 2005 | 32 | 0.110 |
Why?
| | Telomere | 2 | 2015 | 300 | 0.110 |
Why?
| | Patient Care Team | 1 | 2021 | 701 | 0.110 |
Why?
| | Preoperative Care | 3 | 2024 | 396 | 0.110 |
Why?
| | Frail Elderly | 1 | 2015 | 141 | 0.110 |
Why?
| | Image-Guided Biopsy | 1 | 2014 | 41 | 0.110 |
Why?
| | Biliary Tract | 2 | 2012 | 13 | 0.110 |
Why?
| | Acrylic Resins | 2 | 2012 | 48 | 0.100 |
Why?
| | Disease-Free Survival | 4 | 2022 | 778 | 0.100 |
Why?
| | Gene Expression | 1 | 2019 | 1463 | 0.100 |
Why?
| | Gelatin | 2 | 2012 | 56 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 109 | 0.100 |
Why?
| | Abdomen, Acute | 1 | 2014 | 20 | 0.100 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2012 | 141 | 0.100 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.100 |
Why?
| | Cholecystitis | 1 | 2014 | 25 | 0.100 |
Why?
| | Critical Illness | 1 | 2020 | 908 | 0.100 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2013 | 25 | 0.100 |
Why?
| | Linear Models | 3 | 2011 | 857 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2018 | 478 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 192 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 5 | 2013 | 2488 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 251 | 0.100 |
Why?
| | Ventricular Remodeling | 1 | 2016 | 283 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1957 | 0.100 |
Why?
| | Rectal Fistula | 1 | 2013 | 26 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2013 | 1298 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2005 | 70 | 0.100 |
Why?
| | Pattern Recognition, Automated | 1 | 2013 | 74 | 0.100 |
Why?
| | Weight Loss | 1 | 2019 | 858 | 0.100 |
Why?
| | Tetrazoles | 1 | 2013 | 50 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 24 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 1164 | 0.100 |
Why?
| | Postoperative Period | 3 | 2016 | 355 | 0.100 |
Why?
| | Abdominal Neoplasms | 1 | 2013 | 48 | 0.090 |
Why?
| | Protein Phosphatase 1 | 1 | 2013 | 32 | 0.090 |
Why?
| | Liver Circulation | 1 | 2012 | 12 | 0.090 |
Why?
| | Iohexol | 1 | 2012 | 23 | 0.090 |
Why?
| | Endoscopy, Digestive System | 2 | 2024 | 141 | 0.090 |
Why?
| | Academic Medical Centers | 2 | 2013 | 561 | 0.090 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2012 | 9 | 0.090 |
Why?
| | Acute Disease | 3 | 2023 | 1038 | 0.090 |
Why?
| | Polyvinyls | 1 | 2012 | 19 | 0.090 |
Why?
| | Lipase | 1 | 2013 | 76 | 0.090 |
Why?
| | Prednisone | 1 | 2013 | 229 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 541 | 0.090 |
Why?
| | Vascular Neoplasms | 1 | 2012 | 19 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 245 | 0.090 |
Why?
| | Computer Simulation | 1 | 2016 | 1014 | 0.090 |
Why?
| | Electrophysiologic Techniques, Cardiac | 3 | 2018 | 82 | 0.090 |
Why?
| | Peer Review, Research | 1 | 2012 | 36 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 536 | 0.090 |
Why?
| | DNA Methylation | 1 | 2017 | 725 | 0.090 |
Why?
| | Bibliometrics | 1 | 2012 | 68 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2012 | 81 | 0.090 |
Why?
| | Editorial Policies | 1 | 2012 | 46 | 0.090 |
Why?
| | World Health Organization | 2 | 2022 | 104 | 0.090 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 104 | 0.080 |
Why?
| | Precancerous Conditions | 1 | 2012 | 162 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2013 | 286 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 239 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2024 | 314 | 0.080 |
Why?
| | Respiration | 2 | 2017 | 208 | 0.080 |
Why?
| | Coronary Vessels | 1 | 2012 | 245 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1408 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 429 | 0.080 |
Why?
| | Sclerosis | 1 | 2010 | 11 | 0.080 |
Why?
| | Urinary Bladder | 2 | 2022 | 194 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2012 | 267 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 507 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 612 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2022 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 429 | 0.080 |
Why?
| | Splenectomy | 1 | 2010 | 61 | 0.080 |
Why?
| | Pituitary-Adrenal System | 1 | 2011 | 169 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2502 | 0.070 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 204 | 0.070 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 745 | 0.070 |
Why?
| | Saliva | 1 | 2011 | 256 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2013 | 901 | 0.070 |
Why?
| | Ultrasonic Therapy | 1 | 2009 | 16 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2011 | 303 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 530 | 0.070 |
Why?
| | Pilot Projects | 3 | 2019 | 1888 | 0.070 |
Why?
| | Heart | 3 | 2017 | 626 | 0.070 |
Why?
| | Stroke Volume | 2 | 2022 | 652 | 0.070 |
Why?
| | Baltimore | 3 | 2015 | 71 | 0.070 |
Why?
| | Exercise | 2 | 2019 | 2213 | 0.070 |
Why?
| | Organoplatinum Compounds | 2 | 2019 | 65 | 0.070 |
Why?
| | Carcinoma, Islet Cell | 1 | 2008 | 1 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2991 | 0.070 |
Why?
| | Lipids | 1 | 2013 | 714 | 0.070 |
Why?
| | Internet | 1 | 2012 | 660 | 0.060 |
Why?
| | Intestinal Neoplasms | 2 | 2004 | 31 | 0.060 |
Why?
| | Catheterization, Peripheral | 1 | 2008 | 116 | 0.060 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 133 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2013 | 1130 | 0.060 |
Why?
| | Circadian Rhythm | 1 | 2011 | 515 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 992 | 0.060 |
Why?
| | Duodenum | 2 | 2019 | 76 | 0.060 |
Why?
| | Pyridoxal Phosphate | 1 | 2005 | 20 | 0.060 |
Why?
| | Uterus | 1 | 2007 | 227 | 0.060 |
Why?
| | Gallbladder Diseases | 1 | 2005 | 12 | 0.060 |
Why?
| | Edetic Acid | 1 | 2005 | 47 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5899 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 196 | 0.060 |
Why?
| | Sus scrofa | 2 | 2016 | 64 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2025 | 122 | 0.050 |
Why?
| | Iodized Oil | 3 | 2012 | 3 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2019 | 3647 | 0.050 |
Why?
| | Portography | 1 | 2004 | 7 | 0.050 |
Why?
| | Splenic Vein | 1 | 2004 | 2 | 0.050 |
Why?
| | Portal System | 1 | 2004 | 12 | 0.050 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2004 | 5 | 0.050 |
Why?
| | Myometrium | 1 | 2005 | 38 | 0.050 |
Why?
| | Esophagectomy | 1 | 2025 | 136 | 0.050 |
Why?
| | Receptors, Somatostatin | 1 | 2004 | 24 | 0.050 |
Why?
| | Somatostatin | 1 | 2004 | 54 | 0.050 |
Why?
| | Age Factors | 3 | 2018 | 3347 | 0.050 |
Why?
| | Mesenteric Veins | 1 | 2004 | 28 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2004 | 82 | 0.050 |
Why?
| | Calibration | 1 | 2024 | 154 | 0.050 |
Why?
| | Peripheral Vascular Diseases | 1 | 2004 | 102 | 0.050 |
Why?
| | Ovary | 1 | 2025 | 236 | 0.050 |
Why?
| | Body Mass Index | 3 | 2019 | 2458 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2004 | 240 | 0.050 |
Why?
| | Carcinosarcoma | 1 | 2003 | 23 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 117 | 0.050 |
Why?
| | Ipilimumab | 1 | 2023 | 44 | 0.050 |
Why?
| | Pelvis | 1 | 2024 | 129 | 0.050 |
Why?
| | Creatinine | 1 | 2025 | 511 | 0.050 |
Why?
| | Common Bile Duct | 1 | 2022 | 14 | 0.050 |
Why?
| | Intestine, Small | 1 | 2004 | 160 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2006 | 391 | 0.050 |
Why?
| | Heart Aneurysm | 1 | 2002 | 11 | 0.050 |
Why?
| | Child | 5 | 2026 | 22693 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 27 | 0.040 |
Why?
| | Kinetics | 2 | 2017 | 1553 | 0.040 |
Why?
| | Registries | 3 | 2018 | 2400 | 0.040 |
Why?
| | Financing, Organized | 1 | 2022 | 36 | 0.040 |
Why?
| | Heart Failure | 1 | 2015 | 2329 | 0.040 |
Why?
| | Hormones | 1 | 2022 | 134 | 0.040 |
Why?
| | Financing, Government | 1 | 2022 | 53 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2022 | 83 | 0.040 |
Why?
| | Morbidity | 2 | 2013 | 319 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2004 | 284 | 0.040 |
Why?
| | Anilides | 1 | 2021 | 83 | 0.040 |
Why?
| | Pedigree | 2 | 2012 | 512 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 245 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2021 | 179 | 0.040 |
Why?
| | Cholinergic Agents | 1 | 2020 | 18 | 0.040 |
Why?
| | Patient Selection | 2 | 2017 | 728 | 0.040 |
Why?
| | Breast | 1 | 2021 | 155 | 0.040 |
Why?
| | Mitomycin | 2 | 2012 | 31 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2002 | 279 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 157 | 0.040 |
Why?
| | Length of Stay | 2 | 2016 | 1358 | 0.040 |
Why?
| | Appendectomy | 1 | 2000 | 93 | 0.040 |
Why?
| | Aorta | 1 | 2023 | 440 | 0.040 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2020 | 72 | 0.040 |
Why?
| | Hepatitis C | 1 | 2002 | 251 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 462 | 0.040 |
Why?
| | Cachexia | 1 | 2020 | 74 | 0.040 |
Why?
| | Gastroplasty | 1 | 2019 | 31 | 0.040 |
Why?
| | Emergencies | 1 | 2000 | 177 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6073 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 64 | 0.040 |
Why?
| | Pancreatic Function Tests | 1 | 2019 | 4 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 829 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 3017 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2019 | 278 | 0.030 |
Why?
| | Risk | 1 | 2021 | 920 | 0.030 |
Why?
| | Cisplatin | 2 | 2012 | 347 | 0.030 |
Why?
| | Gastric Bypass | 1 | 2019 | 115 | 0.030 |
Why?
| | Paclitaxel | 1 | 2019 | 260 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2026 | 1247 | 0.030 |
Why?
| | Electric Power Supplies | 1 | 2017 | 46 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 693 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.030 |
Why?
| | Equipment Failure | 1 | 2017 | 112 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 78 | 0.030 |
Why?
| | Infant | 3 | 2022 | 10114 | 0.030 |
Why?
| | Zinc Finger Protein Gli3 | 1 | 2016 | 3 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 139 | 0.030 |
Why?
| | Xenopus Proteins | 1 | 2016 | 33 | 0.030 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2017 | 64 | 0.030 |
Why?
| | Pain | 1 | 2022 | 790 | 0.030 |
Why?
| | Radionuclide Imaging | 2 | 2008 | 116 | 0.030 |
Why?
| | Hemorrhage | 1 | 2022 | 825 | 0.030 |
Why?
| | Databases, Factual | 2 | 2016 | 1493 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 467 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2016 | 124 | 0.030 |
Why?
| | Phenotype | 2 | 2015 | 3206 | 0.030 |
Why?
| | Exudates and Transudates | 1 | 2015 | 12 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 594 | 0.030 |
Why?
| | Advisory Committees | 1 | 2017 | 228 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 925 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 543 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3545 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2015 | 29 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 790 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 387 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 311 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 947 | 0.030 |
Why?
| | Sex Factors | 2 | 2015 | 2107 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 520 | 0.030 |
Why?
| | Compressive Strength | 1 | 2014 | 72 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2017 | 874 | 0.020 |
Why?
| | Autoradiography | 1 | 2013 | 65 | 0.020 |
Why?
| | Injections, Intra-Arterial | 1 | 2013 | 25 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2015 | 244 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 365 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2013 | 56 | 0.020 |
Why?
| | Anaplasia | 1 | 2013 | 7 | 0.020 |
Why?
| | Netherlands | 1 | 2013 | 85 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2020 | 1119 | 0.020 |
Why?
| | Research Design | 2 | 2011 | 1143 | 0.020 |
Why?
| | Fractional Flow Reserve, Myocardial | 1 | 2013 | 10 | 0.020 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2013 | 18 | 0.020 |
Why?
| | Pressure | 1 | 2014 | 221 | 0.020 |
Why?
| | Telomerase | 1 | 2015 | 252 | 0.020 |
Why?
| | Molecular Imaging | 1 | 2013 | 58 | 0.020 |
Why?
| | Cicatrix | 1 | 2013 | 72 | 0.020 |
Why?
| | Chromogranins | 1 | 2012 | 13 | 0.020 |
Why?
| | Acyltransferases | 1 | 2013 | 78 | 0.020 |
Why?
| | Radiology, Interventional | 1 | 2013 | 49 | 0.020 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2012 | 44 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2012 | 103 | 0.020 |
Why?
| | Microcirculation | 1 | 2013 | 142 | 0.020 |
Why?
| | Heredity | 1 | 2012 | 13 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 712 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 334 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 160 | 0.020 |
Why?
| | Choice Behavior | 1 | 2013 | 179 | 0.020 |
Why?
| | Mexican Americans | 1 | 2013 | 119 | 0.020 |
Why?
| | Bilirubin | 1 | 2012 | 101 | 0.020 |
Why?
| | Sampling Studies | 1 | 2011 | 97 | 0.020 |
Why?
| | Benzenesulfonates | 1 | 2011 | 23 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 496 | 0.020 |
Why?
| | China | 1 | 2012 | 280 | 0.020 |
Why?
| | Hepatitis B, Chronic | 1 | 2011 | 22 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 270 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 361 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 678 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 102 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2012 | 251 | 0.020 |
Why?
| | Allostasis | 1 | 2011 | 17 | 0.020 |
Why?
| | Europe | 1 | 2012 | 421 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 140 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 379 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2013 | 326 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 329 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2011 | 77 | 0.020 |
Why?
| | Canada | 1 | 2012 | 432 | 0.020 |
Why?
| | Gastroenterology | 1 | 2013 | 187 | 0.020 |
Why?
| | General Surgery | 1 | 2013 | 217 | 0.020 |
Why?
| | Medical Oncology | 1 | 2013 | 345 | 0.020 |
Why?
| | Action Potentials | 1 | 2013 | 500 | 0.020 |
Why?
| | Hepatitis C, Chronic | 1 | 2011 | 150 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 447 | 0.020 |
Why?
| | Sodium Isotopes | 1 | 2009 | 2 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 444 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1712 | 0.020 |
Why?
| | Dexamethasone | 1 | 2011 | 368 | 0.020 |
Why?
| | Thrombosis | 1 | 2012 | 398 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 334 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2006 | 19 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2013 | 733 | 0.010 |
Why?
| | Femoral Artery | 1 | 2007 | 183 | 0.010 |
Why?
| | Mass Screening | 1 | 2014 | 1307 | 0.010 |
Why?
| | Blood Glucose | 1 | 2016 | 2360 | 0.010 |
Why?
| | Gallbladder | 1 | 2005 | 15 | 0.010 |
Why?
| | Child, Preschool | 2 | 2014 | 11913 | 0.010 |
Why?
| | Tissue Survival | 1 | 2005 | 17 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2623 | 0.010 |
Why?
| | Adenoma, Islet Cell | 1 | 2004 | 6 | 0.010 |
Why?
| | Indium Radioisotopes | 1 | 2004 | 12 | 0.010 |
Why?
| | Bone Diseases | 1 | 2005 | 60 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 128 | 0.010 |
Why?
| | Mice | 1 | 2020 | 18297 | 0.010 |
Why?
| | Aneurysm, False | 1 | 2002 | 46 | 0.010 |
Why?
| | Palliative Care | 1 | 2005 | 1032 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1215 | 0.010 |
Why?
|
|
Kamel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|